At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 04 May 2000 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)
- 04 May 2000 Preclinical development for Depression in United Kingdom (Unknown route)